CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $62.69M, above the global median of $16.24M
- FinancialsAltman Z-Score 2.1: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.37BCNY945.12M · vs all stocks (USD)
Revenue (TTM)
2.93BCNY434.84M · vs all stocks (USD)
Profit Margin
-3.42%Beta
0.2560xvs all stocks
52-Week Change
-25.91%vs all stocks
Market Capitalization
6.37BCNY945.12M · vs all stocks (USD)
Enterprise Value
7.23BCNY1.07B · vs all stocks (USD)
Price to Sales (TTM)
2.19xPrice to Book (MRQ)
1.97xEnterprise to Revenue
2.47xEnterprise to EBITDA
32.52xGross Margin
45.89%Profit Margin
-3.42%Operating Margin
10.26%Return on Assets (TTM)
1.02%Return on Equity (TTM)
-3.12%Revenue (TTM)
2.93BCNY434.84M · vs all stocks (USD)
Revenue per Share (TTM)
2.16CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-15.30%Gross Profit (TTM)
1.30BCNY192.53M · vs all stocks (USD)
EBITDA (TTM)
227.61MCNY33.75M · vs all stocks (USD)
Net Income (TTM)
-100.35MCNY-14.88M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
16.60%Operating Cash Flow (TTM)
595.95MCNY88.38M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
422.75MCNY62.69M · vs all stocks (USD)
5-Year Average Dividend Yield
1.12%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
19.28MCNYFY2025 · Dec 31, 2025Revenue
3.05BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.60BCNYFY2025 · Dec 31, 2025Gross Profit
1.44BCNYFY2025 · Dec 31, 2025Operating Income
227.20MCNY33.69M · vs all stocks (USD)
Pre-tax Income
40.47MCNYFY2025 · Dec 31, 2025Income Tax Expense
143.60MCNYFY2025 · Dec 31, 2025Net Income
-103.12MCNYFY2025 · Dec 31, 2025EBIT
44.16MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
227.61MCNYFY2025 · Dec 31, 2025Research & Development
17.96MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
716.64MCNYFY2025 · Dec 31, 2025Other Operating Expenses
43.94MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
634.49KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.69MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0800CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0800CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.30BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.30BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-103.12MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.24MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
786.56MCNYFY2025 · Dec 31, 2025Free Cash Flow
685.20MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
340.89MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-103.12MCNYFY2025 · Dec 31, 2025Other Non-cash Items
69.38MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
382.70MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
437.61MCNYFY2025 · Dec 31, 2025Capital Expenditures
-101.36MCNYFY2025 · Dec 31, 2025Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025Purchase of Investments
-10.00MCNYFY2025 · Dec 31, 2025Sale of Investments
16.47MCNYFY2025 · Dec 31, 2025Other Investing Activity
108.70KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-94.78MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.17BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.72BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-62.48MCNYFY2025 · Dec 31, 2025Other Financing Charges
-17.33MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-636.44MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.40BSharesUpdated Aug 19, 2026Float Shares
1.12BSharesUpdated Aug 19, 2026% Held by Insiders
32.47%vs all stocks
% Held by Institutions
0.42%vs all stocks
Total Cash (MRQ)
180.67MCNY26.79M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1320CNYUpdated Aug 19, 2026Total Debt (MRQ)
1.13BCNY167.82M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3534xCurrent Ratio (MRQ)
0.9460xBook Value per Share (MRQ)
2.33CNYUpdated Aug 19, 2026Total Assets
6.20BCNY919.09M · vs all stocks (USD)
Total Current Assets
2.72BCNYFY2025 · Dec 31, 2025Total Liabilities
3.02BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.47BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
223.14MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.80BCNYFY2025 · Dec 31, 2025Cash
348.71MCNYFY2025 · Dec 31, 2025Cash Equivalents
6.09MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
354.80MCNYFY2025 · Dec 31, 2025Accounts Receivable
1.29BCNYFY2025 · Dec 31, 2025Inventory
665.85MCNYFY2025 · Dec 31, 2025Accounts Payable
764.77MCNYFY2025 · Dec 31, 2025Short-term Debt
1.08BCNYFY2025 · Dec 31, 2025Other Current Liabilities
51.93MCNYFY2025 · Dec 31, 2025Long-term Debt
152.59MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.40BCNYFY2025 · Dec 31, 2025Retained Earnings
1.49BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.17BCNY470.82M · vs all stocks (USD)
Treasury Stock
219.59MCNYFY2025 · Dec 31, 202552-Week Low
4.08CNYUpdated Aug 19, 202652-Week High
6.54CNYUpdated Aug 19, 202652-Week Change
-25.91%vs all stocks
Beta
0.2560xvs all stocks
50-Day MA
4.51CNYUpdated Aug 19, 2026200-Day MA
4.82CNYUpdated Aug 19, 2026Avg 10-Day Volume
8.71MSharesUpdated Aug 19, 2026Avg 30-Day Volume
8.01MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.0800CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.46Profit Margin: -0.03
Financial Health
Altman Z-Score 2.1: grey zoneSignificant
Altman Z-Score: 2.10
High earnings qualityNotable
Earnings Quality Score: 0.93
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $62.69M, above the global median of $16.24MNotable
Levered free cash flow (USD): 62,694,207.021Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Tong Ren Tang Chinese Medicine Company Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Annexon, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arbutus Biopharma Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Green Cross Corporation
Tier 1ProductionApproval-Gated PipelineRule
Youcare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tianjin Tianyao Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hob Biotech Group Suzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kura Oncology Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Geron Corporation
Tier 1ProductionApproval-Gated PipelineRule
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking